Delivery Order SPE2DB24D2109-SPE2DB25FHXPN
- Not listed
- The Defense Logistics Agency awarded a $21,060.94 delivery order to AmerisourceBergen Drug Corp on July 25, 2025, for the supply of Dupixent 300 mg/2 mL pens. This non-competitive, firm fixed price delivery order is expected to be completed by July 28, 2025, and will be fulfilled from the vendor's location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and moderate-to-severe...
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $17,219.89 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 25, 2025. This is a firm fixed price, non-set-aside contract with an ultimate completion date of July 28, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication commonly used to treat moderate-to-severe atopic dermatitis, asthma, and...
- The Defense Logistics Agency awarded a delivery order valued at $10,545.01 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 29, 2025, with an ultimate completion date of July 30, 2025. This competitively awarded, firm fixed-price delivery order carries no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic immunosuppressant used to treat conditions including...
- The Defense Logistics Agency awarded a $14,796.38 delivery order to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Dupixent 300 mg/2 ml pens. This is a firm fixed price, non-set-aside delivery order with an ultimate completion date of August 12, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a specialty biologic medication used to treat conditions including moderate-to-severe atopic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,291.75 for Dupixent 300 mg/2 mL pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This firm fixed-price delivery order was competitively awarded without set-aside restrictions and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat conditions including atopic dermatitis, asthma,...
- The Defense Logistics Agency awarded a delivery order valued at $20,305.35 to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 ml pen injectors on August 7, 2025, with an ultimate completion date of August 8, 2025. This competitively awarded, firm fixed-price delivery order represents a single pharmaceutical procurement under the company's larger Indefinite Delivery Contract with DLA Troop Support Medical. The contract carries no set-aside designation and is being performed at...
- The Defense Logistics Agency awarded a delivery order valued at $7,827.15 to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 mL pens on July 28, 2025, with an ultimate completion date of July 29, 2025. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and will be performed at the contractor's facility in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe eczema, asthma, and other inflammatory...
- The Defense Logistics Agency awarded a delivery order valued at $37,531.67 to AmerisourceBergen Drug Corp for Dupixent 300 mg/2 ml pen injections on August 11, 2025, with an ultimate completion date of August 12, 2025. This firm fixed price, competitively awarded contract (no set-aside used) is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat atopic dermatitis, eosinophilic esophagitis, and asthma,...
- The Defense Logistics Agency awarded a $61,702.19 firm fixed price delivery order to AmerisourceBergen Drug Corp for the supply of Dupixent 300 mg/2 ml pens on July 21, 2025, with an ultimate completion date of July 22, 2025. This contract was competitively awarded with no set-aside designation and is being performed at the contractor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication primarily used to treat moderate-to-severe atopic...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order on July 22, 2025, for Dupixent 300 mg/2 mL pens with a ceiling value of $14,474.85 under a firm fixed price arrangement. The award, which is not set-aside and competitively awarded, is scheduled for completion by July 23, 2025, with performance taking place at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract issued under AmerisourceBergen's...
- SPE2DB24D2109Indefinite Delivery Contract
- SPE2DB24D2109-SPE2DB25FHXPNDelivery Order
The Defense Logistics Agency awarded a $40,070.40 delivery order to AmerisourceBergen Drug Corp for Dupixent 200 mg/1.14 mL pens on July 30, 2025, with an ultimate completion date of July 31, 2025. This competitively awarded, firm fixed-price contract contains no set-aside designation and will be performed at the vendor's corporate office location in Conshohocken, Pennsylvania. Dupixent (dupilumab) is a biologic medication used to treat moderate-to-severe atopic dermatitis, asthma, and other eosinophilic conditions, representing a specialty pharmaceutical product within the Defense Health Agency's medical supply portfolio. This delivery order is a child contract issued under AmerisourceBergen Drug Corp's larger Indefinite Delivery Contract (SPE2DX) with DLA Troop Support Medical, valued at $999,999,999.00 and extending through December 2026. As a major pharmaceutical distributor and critical vendor for federal military healthcare procurement, AmerisourceBergen Drug Corp supplies an extensive range of brand-name and generic medications, vaccines, and medical devices to support military health systems worldwide. The company's role as a prime pharmaceutical vendor demonstrates its capability to fulfill specialized medical requirements across multiple therapeutic domains for Defense Department healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $40.1k | 7/30/25 |